Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.39 Million EUR | -89.81% |
| 2022 | 29.26 Million EUR | 221.48% |
| 2021 | 9.1 Million EUR | 22.07% |
| 2020 | 7.45 Million EUR | -27.24% |
| 2019 | 10.24 Million EUR | 97.29% |
| 2018 | 5.19 Million EUR | 6.98% |
| 2017 | 4.85 Million EUR | 161.78% |
| 2016 | 1.85 Million EUR | 75.66% |
| 2015 | 1.05 Million EUR | -89.94% |
| 2014 | 10.49 Million EUR | 80.54% |
| 2013 | 5.81 Million EUR | 25.85% |
| 2012 | 4.61 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.12 Million EUR | 0.0% |
| 2023 Q4 | 1.12 Million EUR | 0.0% |
| 2023 Q3 | 1.12 Million EUR | 1.67% |
| 2023 FY | 2.98 Million EUR | -89.81% |
| 2023 Q1 | 1.07 Million EUR | -55.33% |
| 2023 Q2 | 1.1 Million EUR | 3.27% |
| 2022 Q2 | 1.7 Million EUR | -86.06% |
| 2022 Q3 | 2.39 Million EUR | 40.53% |
| 2022 Q4 | 2.39 Million EUR | 0.0% |
| 2022 FY | 29.26 Million EUR | 221.48% |
| 2022 Q1 | 12.23 Million EUR | 297.22% |
| 2021 FY | 9.1 Million EUR | 22.07% |
| 2021 Q3 | 2.72 Million EUR | 4.91% |
| 2021 Q4 | 3.08 Million EUR | 13.13% |
| 2021 Q1 | 1.82 Million EUR | 183.25% |
| 2021 Q2 | 2.59 Million EUR | 41.88% |
| 2020 Q2 | 2.27 Million EUR | 23.66% |
| 2020 Q1 | 1.83 Million EUR | -48.9% |
| 2020 Q4 | -2.19 Million EUR | -244.68% |
| 2020 Q3 | 1.51 Million EUR | -33.14% |
| 2020 FY | 7.45 Million EUR | -27.24% |
| 2019 Q1 | 1.7 Million EUR | 152.02% |
| 2019 Q4 | 3.59 Million EUR | 177.1% |
| 2019 Q2 | 3.53 Million EUR | 108.0% |
| 2019 FY | 10.24 Million EUR | 97.29% |
| 2019 Q3 | 1.29 Million EUR | -63.32% |
| 2018 Q2 | 2.04 Million EUR | 17.7% |
| 2018 Q3 | 1.54 Million EUR | -24.4% |
| 2018 FY | 5.19 Million EUR | 6.98% |
| 2018 Q4 | -3.26 Million EUR | -311.8% |
| 2018 Q1 | 1.73 Million EUR | 1.05% |
| 2017 FY | 4.85 Million EUR | 161.78% |
| 2017 Q4 | 1.71 Million EUR | 28.73% |
| 2017 Q3 | 1.33 Million EUR | -9.63% |
| 2017 Q2 | 1.47 Million EUR | -3.66% |
| 2017 Q1 | 1.53 Million EUR | -36.79% |
| 2016 Q2 | 1.1 Million EUR | -10.25% |
| 2016 Q3 | 1.22 Million EUR | 11.42% |
| 2016 Q1 | 1.22 Million EUR | -0.97% |
| 2016 FY | 1.85 Million EUR | 75.66% |
| 2016 Q4 | 2.42 Million EUR | 97.07% |
| 2015 Q2 | 1.48 Million EUR | 4.51% |
| 2015 FY | 1.05 Million EUR | -89.94% |
| 2015 Q4 | 1.24 Million EUR | -20.6% |
| 2015 Q3 | 1.56 Million EUR | 5.47% |
| 2015 Q1 | 1.41 Million EUR | -68.73% |
| 2014 Q3 | 1.87 Million EUR | -40.27% |
| 2014 Q4 | 4.53 Million EUR | 142.46% |
| 2014 Q2 | 3.13 Million EUR | 226.15% |
| 2014 Q1 | 960 Thousand EUR | -45.7% |
| 2014 FY | 10.49 Million EUR | 80.54% |
| 2013 Q4 | 1.76 Million EUR | 4.93% |
| 2013 Q3 | 1.68 Million EUR | 30.12% |
| 2013 Q2 | 1.29 Million EUR | 183.37% |
| 2013 FY | 5.81 Million EUR | 25.85% |
| 2013 Q1 | 457 Thousand EUR | -84.3% |
| 2012 Q3 | 1.09 Million EUR | 0.0% |
| 2012 FY | 4.61 Million EUR | 0.0% |
| 2012 Q4 | 2.91 Million EUR | 166.58% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 70.725% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -141453.836% |
| SQZ Biotechnologies Company | 9.79 Million USD | 55.166% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 62.489% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 96.313% |
| Mesoblast Limited | -35.16 Million USD | 112.486% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 12957.98% |
| Genus plc | 178.7 Million USD | 97.543% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -970.545% |
| Marizyme, Inc. | 457.7 Thousand USD | -859.358% |
| ContraFect Corporation | -154 Thousand USD | 2951.299% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 40018.182% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 8882.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -5620.353% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -6580.562% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1233.158% |
| MultiCell Technologies, Inc. | 49.32 USD | -8902981.914% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 89.095% |
| EV Biologics, Inc. | 48.9 Thousand USD | -8879.55% |
| Q BioMed Inc. | -8988.00 USD | 48954.028% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 84.459% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 28568.62% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 98.005% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -6172.857% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 3633.976% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -6956.536% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 88771.244% |
| Arch Therapeutics, Inc. | -2439.00 USD | 180132.8% |
| IMV Inc. | -962.29 Thousand USD | 556.304% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -3025.267% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 4602.897% |
| GB Sciences, Inc. | -624.00 USD | 703785.897% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 5204.152% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.942% |
| Halberd Corporation | -208.00 USD | 2111157.692% |
| Enzolytics Inc. | 30.7 Thousand USD | -14199.205% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -223.547% |
| SYBLEU INC | 11.69 Thousand USD | -37442.75% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -810.178% |
| argenx SE | 1.1 Billion USD | 99.604% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 117.021% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -611.227% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 98.928% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 49682.204% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 90.101% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 484.645% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -344.442% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 54.313% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 5336.795% |
| BioStem Technologies, Inc. | 15.42 Million USD | 71.533% |
| ONE Bio Corp. | 20.12 Million USD | 78.182% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 37201.817% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 9198.821% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2386.973% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2386.973% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 953.433% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 796.831% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 15241.379% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -875.685% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1474.305% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 4.709% |
| Bioxytran, Inc. | -8285.00 USD | 53099.396% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 1277.212% |
| Neutra Corp. | 14.33 Thousand USD | -30531.322% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 5454.878% |
| PureTech Health plc | -1.6 Million USD | 373.924% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 538.558% |
| IXICO plc | 3.27 Million USD | -34.281% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 732.709% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 345.17% |
| CSL Limited | 7.7 Billion USD | 99.943% |
| Cellectis S.A. | 18 Thousand USD | -24294.444% |